$ORCL

Oracle and Wild Bio collab to advance AI-powered agriculture

Wild Bioscience (Wild Bio) and Oracle have partnered to advance agricultural resilience and crop-based carbon removal using AI. Wild Bio will use Oracle Cloud and IoT tech for field research, focusing on crop productivity and carbon dioxide removal. Oracle's tech will capture and analyze field data to inform Wild Bio's research. The collaboration supports Oracle's sustainability goals, including net-zero emissions by 2050.

Original reporting
Published Sep 24, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oracle and Wild Bio collab to advance AI-powered agriculture — source image
Decision brief

The 30-second read

$ORCLBullishLow
01

Why it matters

The collaboration could generate incremental cloud usage and data services revenue for Oracle, while positioning Wild Bio as a leader in AI‑enabled sustainable agriculture.

02

Market read

First‑time announcement of a strategic partnership linking cloud AI services with agricultural carbon‑removal research.

03

What to watch

Regulatory or adoption hurdles in farming communities could delay commercial benefits.

Relevance 5/10Novelty 6/10Timing: today

Background

Oracle is expanding its cloud and IoT offerings into new verticals; Wild Bioscience is a UK spin‑out focused on crop genetics and carbon‑removal traits.

Company-level read

Ticker impact

$ORCLBullishMedium confidence
Context

Oracle announced a new collaboration with Wild Bioscience to use Oracle Cloud and IoT for AI‑driven agricultural resilience and carbon‑removal research.

Expected impact

Modest short‑term bullish pressure if investors view the partnership as a growth catalyst.

Evidence & confidence

The deal expands Oracle's addressable market into agriculture, but no financial terms were disclosed.

Market effects

Highlights growing interest in AI applications for agriculture, may benefit broader agritech and cloud service providers.

UK and US agritech ecosystems could see increased collaboration activity.

Shows cross‑border tech partnerships targeting climate‑focused agriculture.

Counterpoint

Without disclosed financial terms, the partnership may have limited revenue impact for Oracle.

Key entities

  • Oracle

    US‑listed cloud and software provider (ticker ORCL).

  • Wild Bioscience

    UK‑based agritech startup specializing in crop genetics.

Related articles

$ORCLMed

Oracle, Bloom in focus after Trump’s data center power push

President Trump mandated large data centers to generate their own electricity, benefiting Oracle (ORCL) and Bloom Energy (BE), who already implement such plans. Oracle faces high costs for trucked gas due to pipeline delays, impacting its negative cash flow. Bloom's shares have doubled, while Oracle's have fallen 53%. Bloom reports Q3 results, which may update progress on Oracle's New Mexico project.

$ORCLLow

Report: Larry Ellison Borrowed Billions for Warner Deal

Larry Ellison borrowed billions, using Oracle, Tesla, SpaceX, and Paramount Skydance shares as collateral, to fund his son's Warner Bros. Discovery takeover. He pledged 87 million Oracle shares, up from 30 million a year ago, potentially supporting $5.7 billion in loans. Oracle's board reviews these arrangements quarterly.

$ORCLMed

TD Cowen Raises Possibility of Nvidia Credit Support for Oracle

TD Cowen suggested Nvidia may be providing credit support to Oracle for its AI infrastructure. Oracle's capital expenditures rose to $28.5B, with negative free cash flow of $5.4B. Oracle has $288B in lease commitments, mostly for data centers. Nvidia reported $89B in data center revenue. Oracle raised $48B in fiscal 2026 and plans $40B more in fiscal 2027.

$ORCLMed

Oracle Stocks Rise 2.4% as AstraZeneca Pact Opens an AI Healthca

Oracle (ORCL) shares rose 2.4% after announcing a nonbinding AI collaboration with AstraZeneca to explore clinical research and care workflows. The partnership's size, timing, and commercial terms are yet to be determined. Oracle aims to demonstrate how its technology can improve healthcare processes. The company's GF Score is 88/100, indicating strong profitability and growth, but valuation and balance-sheet questions remain.